KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Novartis Ag (NVS) over the last 17 years, with Q4 2025 value amounting to $11.4 billion.

  • Novartis Ag's Cash & Equivalents fell 20.94% to $11.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $11.4 billion, marking a year-over-year decrease of 20.94%. This contributed to the annual value of $11.4 billion for FY2025, which is 20.94% down from last year.
  • Novartis Ag's Cash & Equivalents amounted to $11.4 billion in Q4 2025, which was down 20.94% from $9.6 billion recorded in Q3 2025.
  • In the past 5 years, Novartis Ag's Cash & Equivalents ranged from a high of $6000.0 billion in Q1 2021 and a low of $70.0 million during Q1 2022
  • In the last 5 years, Novartis Ag's Cash & Equivalents had a median value of $10.3 billion in 2021 and averaged $309.3 billion.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 789463684.21% in 2021, then plummeted by 9999.88% in 2022.
  • Quarter analysis of 5 years shows Novartis Ag's Cash & Equivalents stood at $12.4 billion in 2021, then tumbled by 39.41% to $7.5 billion in 2022, then skyrocketed by 78.17% to $13.4 billion in 2023, then decreased by 14.44% to $11.5 billion in 2024, then dropped by 0.21% to $11.4 billion in 2025.
  • Its Cash & Equivalents was $11.4 billion in Q4 2025, compared to $9.6 billion in Q3 2025 and $6.7 billion in Q2 2025.